COLLOQUE - LISBON CONFERENCE - 14-15 JANVIER 2010 - PANEL IV

Lisbon Conference - Panel IV - Intellectual property and competition - complementary policies? The case of the software and pharmaceutical industries (15 January 2010)

Does patent protection restrict U.S. drug use? The impact of patent expiration on U.S. drug prices, marketing, and utilization Franck R. LICHTENBERG*, Columbia University National Bureau of Economic Research, Faculty Fellow, Lerner Center Gautier DUFLOS*, University of Paris I, Paris School of Economics * We are extremely grateful to the Blanche & Irwin Lerner Center for Pharmaceutical Management Studies at Rutgers University, and to its Director, Mahmud Hassan, for providing IMS Health data to us. I. Background and objectives 1. U.S. patent law is based on Article I, Section 8 of the Constitution, which states that “the Congress shall have power to promote the Progress of Science and useful Arts, by securing for limited Times to Authors and Inventors the exclusive Right to

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Jones Day (Brussels)
  • Microsoft (Geneva)
  • Sciences Po Paris
  • Columbia University (New York)
  • US Federal Trade Commission (FTC) (Washington)
  • University of California (Berkeley)
  • Visa (London)

Quotation

Eric Morgan de Rivery, Jean-Yves Art, Gautier Duflos, Frank Lichtenberg, David Schmidt, Richard Gilbert, Julia Holtz, Lisbon Conference - Panel IV - Intellectual property and competition - complementary policies? The case of the software and pharmaceutical industries (15 January 2010), May 2010, Concurrences N° 2-2010, Art. N° 31078, www.concurrences.com

Visites 2527

All reviews